Psoriasis clinical trials at UC Irvine

1 research study open to eligible people

Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis
open to eligible people ages 6-17
The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.
Orange, California and other locations

Last updated: December 11, 2024